Literature DB >> 22032309

Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.

A J Low1, D Fowler, M K Manghani, I Young, R Garsia, P Torzillo, P Youssef, D S Celermajer.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is an increasingly recognised serious illness with insidious onset, delayed diagnosis, complex diagnostic algorithms and poor prognosis, but with recently available effective treatments. AIMS: To efficiently diagnose and to offer treatment for PAH, we established a multidisciplinary service in 2005, where patients attend a clinic staffed by specialists in cardiology, respiratory medicine, rheumatology and immunology in a tertiary referral hospital setting.
METHODS: We studied the first 200 patients referred. Serology, echocardiography, lung function tests, high-resolution computed tomography, World Health Organisation Class determination and 6-min walk tests and/or right heart catheterisation were performed, as clinically indicated.
RESULTS: Of the 200 patients seen, 66 had confirmed pulmonary hypertension (mean pulmonary artery pressure > 25 mmHg) diagnosed on echocardiography ± right heart catheterisation. Of these patients, 58 had catheter-proven PAH (mean pulmonary artery pressure > 25 mmHg with mean wedge pressure < 15 mmHg). Underlying diagnoses for the confirmed PAH patients were idiopathic (32), scleroderma-associated (14), other connective tissue disease (4) and associated with congenital heart disease (8). Patients with confirmed PAH were commenced on PAH-specific therapy--initially bosentan in the majority but sildenafil, and iloprost were occasionally used initially for patient-specific reasons. Median time from when the patient first called the clinic to prescription of therapy was 16 days (interquartile range; 0-31 days). All surviving patients with PAH have attended for regular 6-monthly follow-up visits with a 100% retention rate up to 4 years.
CONCLUSION: A multidisciplinary clinic can provide efficient diagnosis and rapid triage to PAH-specific therapy, if appropriate. Retention rates remain high, at follow up.
© 2011 The Authors; Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22032309     DOI: 10.1111/j.1445-5994.2011.02624.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  2 in total

1.  Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Authors:  Sophia Emmons-Bell; Catherine Johnson; Alexandra Boon-Dooley; Paul A Corris; Peter J Leary; Stuart Rich; Magdi Yacoub; Gregory A Roth
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

2.  An international physician survey of pulmonary arterial hypertension management.

Authors:  Ioana R Preston; Barbara Hinzmann; Sabina Heinz; Henning Gall; David Jenkins; Nick H Kim; Irene Lang
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.